XNYS · SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH · SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH
Includes notes from domestic 8-K and foreign private issuer 6-K disclosures.
TL;DR: Charles River Laboratories reported Q1 2026 revenue of $995.8 million, up 1.2% from $984.2 million a year ago, while non-GAAP EPS came in at $2.06 versus $2.34 in Q1 2025 — a 12% decline. The GAAP headline looks u…
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 5/8/2026 | Graves Paul W | — | GRANT | 1,438 | $178 | $255,418 |
| 5/8/2026 | Thompson Craig B. | — | GRANT | 1,438 | $178 | $255,418 |
| 5/8/2026 | Barg Steven | — | GRANT | 1,438 | $178 | $255,418 |
| 5/8/2026 | Ceesay Abraham | — | GRANT | 1,438 | $178 | $255,418 |
| 5/8/2026 | MACKAY MARTIN | — | GRANT | 1,438 | $178 | $255,418 |
| 5/8/2026 | MACKAY MARTIN | — | GRANT | 1,407 | $178 | $249,911 |
| 5/8/2026 | Andrews Nancy C | — | GRANT | 1,438 | $178 | $255,418 |
| 5/8/2026 | Llado George Sr. | — | GRANT | 1,438 | $178 | $255,418 |
| 5/8/2026 | Llado George Sr. | — | GRANT | 450 | $178 | $79,929 |
| 5/8/2026 | Enyedy Mark J | — | GRANT | 1,438 | $178 | $255,418 |
| 5/8/2026 | Kemps-Polanco Reshema | — | GRANT | 1,438 | $178 | $255,418 |
| 5/8/2026 | Kemps-Polanco Reshema | — | GRANT | 535 | $178 | $95,027 |
| 5/8/2026 | WILSON VIRGINIA M | — | GRANT | 1,438 | $178 | $255,418 |
| 5/8/2026 | FOSTER JAMES C | — | GRANT | 1,438 | $178 | $255,418 |
| 5/8/2026 | FOSTER JAMES C | — | GRANT | 422 | $178 | $74,956 |
| 5/1/2026 | Coleman Glenn | EVP & Chief Financial Officer | GRANT | 21,112 | $166 | $3,499,947 |
| 3/4/2026 | Girshick Birgit | Corporate Executive VP & COO | GIFT | -328 | — | — |
| 3/3/2026 | LaPlume Joseph W | EVP, Corp Strategy & Develop | BUY | 25 | $175 | $4,364 |
| 3/2/2026 | FOSTER JAMES C | Chairman, President and CEO | GRANT | 16,796 | $179 | $2,999,934 |
| 1/30/2026 | LaPlume Joseph W | EVP, Corp Strategy & Develop | GRANT | 5,456 | — | — |